Becton, Dickinson and Company (NYSE:BDX) Posts Earnings Results, Beats Expectations By $0.08 EPS

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.08, FiscalAI reports. The business had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.96 earnings per share.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• BD reported Q4 revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%. For fiscal 2026, revenue increased 3.9% to $19.5 billion and adjusted EPS rose 6.7% to $12.70.
• Executives cited broad momentum in growth platforms, including Advanced Patient Monitoring, PureWick, biologic drug delivery, advanced tissue regeneration, and Rowa pharmacy automation. They also highlighted share gains in Alaris and strong adoption of the Incada AI platform, while noting these results reflect targeted commercial and capacity investments.
• Fiscal 2027 guidance calls for low-single-digit revenue growth and adjusted EPS of $13.10–$13.30, with operating margins roughly flat. Excluding an estimated 200-basis-point Alaris comparison headwind, revenue growth is expected to be mid-single-digit at the midpoint; Q1 growth is expected at the low end of the annual range.
• Full-year free cash flow rose 42% to $2.9 billion, and conversion improved to approximately 74%, including separation costs; BD expects another meaningful step-up in fiscal 2027. The company returned $3.6 billion to shareholders and said its capital allocation priorities include buybacks, debt reduction, and focused tuck-in acquisitions.
• BD agreed to invest $19 billion in the U.S. over several years, including $3 billion for manufacturing expansion; management said this is a reprioritization of planned investment, not incremental spending. Potential relief from future Section 232 tariffs is not included in guidance and depends on final rules and the company meeting agreed milestones.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded down $1.28 during midday trading on Friday, reaching $212.27. 2,172,550 shares of the company were exchanged, compared to its average volume of 1,599,485. The stock’s 50-day moving average price is $188.17 and its 200-day moving average price is $170.28. The stock has a market cap of $58.49 billion, a P/E ratio of 51.27, a PEG ratio of 13.39 and a beta of 0.22. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a one year low of $137.35 and a one year high of $214.88.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be given a $1.06 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,907 shares of company stock valued at $1,269,128 in the last 90 days. 0.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on BDX. TD Cowen lifted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Jefferies Financial Group restated a “buy” rating and issued a $242.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday. Royal Bank Of Canada boosted their price target on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research note on Friday. Finally, Bank of America boosted their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $193.67.

Becton, Dickinson and Company announced that its board has authorized a share repurchase program on Thursday, November 5th that authorizes the company to buy back 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 3.6% of its shares through open market purchases. Share buyback programs are generally an indication that the company’s management believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.